A Randomized, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Prevention of Recurrence in Subjects With Bipolar I Disorder

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Prevention of Recurrence in Subjects With Bipolar I Disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Lurasidone (Primary) ; Lithium; Valproate semisodium
  • Indications Bipolar I disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms PERSIST
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 31 Mar 2017 Results from this trial will be presented at the 25th European Congress of Psychiatry (EPA 2017), according to a Sunovion Pharmaceuticals media release.
    • 07 Apr 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 17 Feb 2015 Planned End Date changed from 1 Jan 2015 to 1 Apr 2015 bas reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top